A phase 1 study evaluating the safety, reactogenicity and immunogenicity of SCB-2019, a vaccine candidate for coronavirus disease 2019 (COVID-19), has been initiated by Clover Biopharmaceuticals.
Since January 2020, when China shared the whole genome sequence, researchers have been working tirelessly to create a potential vaccine.
A team of investigators report on the findings from a randomized controlled trial of 3 enhanced influenza vaccines and a standard-dose vaccine in older adults.
The decline in vaccination rates during the SARS-CoV-2 pandemic could lead to global outbreaks of communicable infectious diseases.
The purpose of this project is to implement and evaluate the effectiveness of the 4 Pillars Practice Transformation Program to increase uptake of the HPV vaccine among pediatric patients.
What are the top 3 things that rheumatologists need to know about vaccines in rheumatic diseases?
Researchers determined the risk for Guillain-Barré Syndrome following seasonal influenza vaccination in a real-world study.
Researchers assessed protective antibody responses to diphtheria and tetanus vaccination in patients with polyarticular-course juvenile idiopathic arthritis.
Implementation of an influenza immunization program increased vaccinations rates from 44% to 57% the following year.
Primary vaccination against hepatitis B virus (HBV) at birth may not provide adequate lifelong antibody levels, but a booster vaccine at age 18 years reinforces antibody levels for at least 4 more years.
